Value of serum NT proBNP, HMGB1, and SIRT1 in the diagnosis and prognosis of neonatal respiratory distress syndrome.

OBJECTIVE

To analyze the value of serum aminoterminal pro-brain natriuretic peptide (NT-proBNP), High mobility group protein B1(HMGB1), and silent information regulator factor 2 related enzyme 1 (SIRT1) in the diagnosis and prognosis of neonatal respiratory distress syndrome (NRDS).

METHODS

This was a retrospective study. Eighty cases of NRDS infants were selected in Maternity & Child Care Center of Qinhuangdao from January 2022 to January 2024 as the study group, with 80 cases of normal newborns during the same period selected as the control group. The NRDS infants were divided into the excellent prognosis group (n=49) and the poor prognosis group (n=31). The levels of serum NT-proBNP, HMGB1, and SIRT1 were compared among the groups, along with an investigation of the value of these biomarkers for the diagnosis and prognosis of NRDS infants.

RESULTS

The study group exhibited higher levels of serum NT-proBNP and HMGB1(P< 0.05) and lower levels of serum SIRT1(P< 0.05) than the control group. The ROC curve analysis suggested that AUC values for serum NT-proBNP, HMGB1, SIRT1, and their combination in the diagnosis of NRDS were 0.903, 0.829, 0.794, and 0.958, respectively. The ROC curve analysis showed that AUC values for serum NT-proBNP, HMGB1, SIRT1, and their combination in predicting poor prognosis in NRDS infants were 0.810, 0.813, 0.741, and 0.935, respectively.

CONCLUSION

The combination of serum NT-proBNP, HMGB1, and SIRT1 may demonstrate a high diagnostic value for NRDS infants, as well as a high predictive value for poor prognosis in such infants.